SynthesisBMJ open respiratory research2026
Impact of time to diagnosis in patients with progressive fibrotic ILD: a systematic review.
Synthesis in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProgressive fibrosing interstitial lung diseases (PF-ILDs), including idiopathic pulmonary fibrosis (IPF), are characterised by irreversible fibrosis and poor prognosis. Despite the importance of timely identification, diagnostic delays remain common. This review aimed to summarise studies reporting time to diagnosis in PF-ILDs to identify reasons for diagnostic delays and the impact on several clinical and economic outcomes.
methodsDatabase (Embase, MEDLINE, Cochrane Library, LILACS and grey literature) searches were conducted on 15 July 2024 and updated on 5 June 2026. Observational studies reporting time to diagnosis in PF-ILD published between 2002 and 2026 were identified.
results34 studies representing 36 621 patients from 41 countries met the inclusion criteria. Dyspnoea, cough and fatigue were the most common presenting symptoms. Median time from symptom onset to diagnosis ranged between 6.0 and 25.2 months; mean estimates varied from 9.6 to 39.3 months in IPF and exceeded 30.2 months in non-IPF PF-ILD. Between 30% and 77% of patients experienced delays >12.0 months. An increased diagnostic time was associated with more advanced disease, worse survival, poorer quality of life and increased hospitalisation rate. Across included studies, between 21% and 87% of patients were misdiagnosed (often with cardiovascular or other respiratory diseases) and received treatment for other conditions. Predictors of delayed diagnosis included older age, comorbidities, misdiagnosis, previous therapy and absence of early imaging or multidisciplinary evaluation.
conclusionsPatients with PF-ILD, including IPF, face a long time to diagnosis, associated with unfavourable clinical and healthcare resource outcomes, with limited evidence on cost outcomes. Direct economic burden resulting from delayed diagnosis is currently poorly understood and needs further research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.